Blog

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Blog

Peter Schmid’s findings on atezolizumab and sacituzumab govitecan for advanced TNBC – ESMO

Photo taken from ESMO/X

Jun 29, 2024, 03:18

Peter Schmid’s findings on atezolizumab and sacituzumab govitecan for advanced TNBC – ESMO

ESMO shared a post on LinkedIn:

“For ESMO members: Breaking Science in Breast Cancer.
Peter Schmid presents his findings on atezolizumab and sacituzumab govitecan for advanced Triple-negative breast cancer (TNBC).
Explore this video and others from this series on OncologyPRO now.”

Additional information
Source: ESMO/LinkedIn

atezolizumab cancer ESMO OncoDaily Oncology OncologyPro Peter Schmid Sacituzumab govitecan TNBC triple-negative breast cancer

Jul 3, 2024, 06:24

Aaron Goodman's advice for the new interns

Jul 3, 2024, 06:20

Nicole Collantes: Finished my rotation in the CCU at Jackson Memorial Hospital

Jul 3, 2024, 06:13

Busra Cangut: Honored to be invited as a moderator for the poster session at the WTS Annual Meeting

Jul 3, 2024, 06:03

Is de-escalation of adjuvant treatment safe in stage I HER2+ tumors larger than 1 cm?

Jul 3, 2024, 05:47

Keynote lecture on liver cancer by Stephen L Chan

Jul 3, 2024, 04:18

FDA and WHOSTP discuss increasing clinical trials access and lowering barriers to participation

Jul 3, 2024, 04:02

Sachin H. Jain: Our broken culture of communications

Jul 3, 2024, 03:34

Anirban Maitra: Gene on new preprint from Lowy Lab, UC San Diego Health Moores Cancer Center

Jul 3, 2024, 03:24

Lumír Kunovský: Harvard University on management of pancreatic disorders for the practicing clinicians

Jul 3, 2024, 03:15

Partnership of HUG and the National Cancer Center of Mongolia to advance cancer care in Mongolia

Jul 3, 2024, 02:47

Seyed Alireza Javadinia: Oesophago-gastric cancer on the third day of ESMOGI24

Jul 3, 2024, 02:46

Malak Alharbi: Stephen V. Liu discusses treatment algorithm for early-stage NSCLC